polo like kinase 3Genealiases: CNK · FNK · PLK-3 · PRK
Q-omics provides the consensus-scored PLK3 profile across patient tissues and cancer cell-line models. PLK3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PLK3 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, PLK3 RNA expression shows 18,565 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where PLK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLK3 survival associations across molecular data types. PLK3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLK3 RNA expression–survival associations across cancer types. High PLK3 expression shows unfavorable associations in ACC, LGG, LUSC, MESO and KIRC, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PLK3 RNA expression.
This table summarizes PLK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PLK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLK3 shows lower tumor expression in KICH, BRCA and LUSC and higher tumor expression in THCA, COAD and KIRC. The THCA box plot shows higher PLK3 RNA expression in tumor versus normal tissue (log2 FC = +1.664, t-test p < 0.001).
This table shows molecular features associated with PLK3 in patient tissues and cancer cell lines. In patient samples, PLK3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
